Abcam, ab7613, Anti-Apolipoprotein A I antibody

Size: 100µg
Goat Polyclonal Apolipoprotein A I antibody. Suitable for IP, ELISA, WB, IHC-P and reacts with Human samples. Cited in 42 publications. Immunogen corresponding to Native Full Length Protein corresponding to Human APOA1.
Key facts
Host species:Goat,
Clonality:Polyclonal,
Isotype:IgG,
Carrier free:No,
Reacts with:Human,
Applications:ELISA, WB, IHC-P, IPSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:Native Full Length Protein corresponding to Human APOA1.P02647,
Specificity:Typically less than 1% cross-reactivity against other types of apoLipoprotein was detected by ELISA against purified standards. This antibody reacts with human apoLipoprotein A-I and has negligible cross-reactivity with Type A-II, B, C-I, C-II, C-III, E and J apoLipoproteins. Specific cross-reaction of anti-apoLipoprotein antibodies with antigens from other species has not been determined. Non-specific cross-reaction of anti-apoLipoprotein antibodies with other human serum proteins is negligible.

Product details:
This antibody has been used to determine that atherosclerotic lesions in the human aorta contain considerable amounts of lipoproteins. These lipoproteins were observed to be complexed with components of the extracellular matrix (especially LDL and proteoglycans). The role of these matrix-lipoprotein complexes is not entirely clear, however, animal models of atherosclerosis have shown that increased cellular proliferation and increased production of extracellular matrix components occur following injury to the intimal layer of the aorta.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Immunogen, Purification notes-This product has been prepared by immunoaffinity chromatography using immobilized antigens followed by extensive cross-adsorption against other apoLipoproteins and human serum proteins to remove any unwanted specificities., Storage buffer-pH: 8 Preservative: 0.01% Sodium azide Constituents: 4.77% Sodium borate, 0.44% Sodium chloride, 0.15% EDTA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Apolipoprotein A-I (ApoA-I) is a major component of high-density lipoprotein (HDL) particles often referred to as 'good cholesterol'. It has a molecular mass of approximately 28 kDa. ApoA-I is mainly expressed in the liver and intestine. It plays a mechanical role in the reverse transport of cholesterol acting to facilitate the efflux of cholesterol from tissues to the liver for excretion. Its alternative names include ApoAI ApoA1 and a component of the AI kits used for measuring this protein.
Biological function summary
ApoA-I functions in cholesterol homeostasis and inflammation. It is a structural component of the HDL complex that mobilizes cholesterol. ApoA-I acts as an activator of the enzyme lecithin-cholesterol acyltransferase (LCAT) which is essential for the maturation of HDL particles. This maturation is necessary for effective cholesterol transport and clearance. ApoA-I's ability to stabilize HDL particles and enhance their functionality makes it significant for maintaining lipid balance and cellular homeostasis.
Pathways
The interaction of ApoA-I with HDL formation and function marks its role in lipid metabolism pathways. Its participation in the reverse cholesterol transport pathway highlights its influence on cardiovascular health. ApoA-I also interacts with other proteins like ApoA-II and paraoxonase-1 which further influence lipid metabolism and antioxidant activities. Understanding these relationships helps elucidate the dynamics of cholesterol removal from the bloodstream.
Disturbances in ApoA-I levels correlate with cardiovascular disease and atherosclerosis. Deficiency or dysfunction in ApoA-I can impair HDL function leading to poor cholesterol removal and buildup within arteries. It is also connected to amyloidosis where misfolded ApoA-I forms deposits in tissues. Understanding these pathological conditions helps researchers target ApoA-I in therapeutic strategies to mitigate disease progression often studying it alongside proteins like ApoB which is associated with low-density lipoprotein (LDL) particles.